後天性希少血液疾患治療薬の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)

【英語タイトル】Global Acquired Orphan Blood Diseases Therapeutics Market by Manufacturers, Countries, Type and Application, Forecast to 2023

GlobalInfoResearchが出版した調査資料(GIR8100012)・商品コード:GIR8100012
・発行会社(調査会社):GlobalInfoResearch
・発行日:2018年10月23日
・ページ数:129
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:世界
・産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥379,320見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥568,980見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥758,640見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは、後天性希少血液疾患治療薬の世界市場について調べ、まとめました。種類別セグメントは、薬、骨髄移植、輸血、鉄療法等、用途別セグメントは、病院、診療所、その他等に区分しました。後天性希少血液疾患治療薬の世界市場概観、メーカー動向、メーカー別後天性希少血液疾患治療薬シェア、市場規模推移、市場規模予測、主要地域分析(北米、ヨーロッパ、アジア等)、主要国分析(日本、中国、アメリカ等)データなどの情報が含まれています。
・後天性希少血液疾患治療薬の市場概観
・後天性希少血液疾患治療薬のメーカー概要(事業概要、製品種類、価格、売上、市場シェア等)
・後天性希少血液疾患治療薬のメーカー別販売動向、市場シェア、市場集中度、競争動向
・後天性希少血液疾患治療薬の世界市場規模
・後天性希少血液疾患治療薬の北米市場分析(アメリカ、カナダ、メキシコ等)
・後天性希少血液疾患治療薬のアメリカ市場規模推移
・後天性希少血液疾患治療薬のカナダ市場規模推移
・後天性希少血液疾患治療薬のメキシコ市場規模推移
・後天性希少血液疾患治療薬のヨーロッパ市場分析(ドイツ、イギリス、ロシア、フランス、イタリア等)
・後天性希少血液疾患治療薬のドイツ市場規模推移
・後天性希少血液疾患治療薬のイギリス市場規模推移
・後天性希少血液疾患治療薬のロシア市場規模推移
・後天性希少血液疾患治療薬のアジア市場分析(日本、中国、韓国、インド、東南アジア等)
・後天性希少血液疾患治療薬の日本市場規模推移
・後天性希少血液疾患治療薬の中国市場規模推移
・後天性希少血液疾患治療薬の韓国市場規模推移
・後天性希少血液疾患治療薬のインド市場規模推移
・後天性希少血液疾患治療薬の東南アジア市場規模推移
・後天性希少血液疾患治療薬の南米市場分析(ブラジル、アルゼンチン等)
・後天性希少血液疾患治療薬の中東・アフリカ市場分析(サウジアラビア、UAE、南アフリカ等)
・後天性希少血液疾患治療薬の種類別分析/市場規模推移(薬、骨髄移植、輸血、鉄療法)
・後天性希少血液疾患治療薬の用途別分析/市場規模推移(病院、診療所、その他)
・後天性希少血液疾患治療薬の市場予測(地域別予測、種類別予測、用途別予測)
・後天性希少血液疾患治療薬の販売チャネル・代理店・貿易業者・ディーラー分析
【レポートの概要】

Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.

Scope of the Report:

This report studies the Acquired Orphan Blood Diseases Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Acquired Orphan Blood Diseases Therapeutics market by product type and applications/end industries.

Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody 

The global Acquired Orphan Blood Diseases Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Acquired Orphan Blood Diseases Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Alexion Pharmaceuticals

Amgen

Celgene Corporation

Eli Lilly

Sanofi

GlaxoSmithKline

Cyclacel Pharmaceuticals

Onconova Therapeutics

Incyte Corporation

CTI BioPharma

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Medication

Bone Marrow Transplant

Blood Transfusion

Iron Therapy

Market Segment by Applications, can be divided into

Hospitals

Clinics

Others

【レポートの目次】

Table of Contents

1 Acquired Orphan Blood Diseases Therapeutics Market Overview

1.1 Product Overview and Scope of Acquired Orphan Blood Diseases Therapeutics

1.2 Classification of Acquired Orphan Blood Diseases Therapeutics by Types

1.2.1 Global Acquired Orphan Blood Diseases Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Types in 2017

1.2.3 Medication

1.2.4 Bone Marrow Transplant

1.2.5 Blood Transfusion

1.2.6 Iron Therapy

1.3 Global Acquired Orphan Blood Diseases Therapeutics Market by Application

1.3.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global Acquired Orphan Blood Diseases Therapeutics Market by Regions

1.4.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Acquired Orphan Blood Diseases Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Acquired Orphan Blood Diseases Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acquired Orphan Blood Diseases Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Acquired Orphan Blood Diseases Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acquired Orphan Blood Diseases Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Acquired Orphan Blood Diseases Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 Alexion Pharmaceuticals

2.1.1 Business Overview

2.1.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Amgen

2.2.1 Business Overview

2.2.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Amgen Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 Celgene Corporation

2.3.1 Business Overview

2.3.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 Eli Lilly

2.4.1 Business Overview

2.4.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 Sanofi

2.5.1 Business Overview

2.5.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Sanofi Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.6 GlaxoSmithKline

2.6.1 Business Overview

2.6.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.7 Cyclacel Pharmaceuticals

2.7.1 Business Overview

2.7.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.8 Onconova Therapeutics

2.8.1 Business Overview

2.8.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.9 Incyte Corporation

2.9.1 Business Overview

2.9.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.10 CTI BioPharma

2.10.1 Business Overview

2.10.2 Acquired Orphan Blood Diseases Therapeutics Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Acquired Orphan Blood Diseases Therapeutics Market Competition, by Players

3.1 Global Acquired Orphan Blood Diseases Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Acquired Orphan Blood Diseases Therapeutics Players Market Share

3.2.2 Top 10 Acquired Orphan Blood Diseases Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions

4.1 Global Acquired Orphan Blood Diseases Therapeutics Revenue and Market Share by Regions

4.2 North America Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Acquired Orphan Blood Diseases Therapeutics Revenue by Countries

5.1 North America Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

5.2 USA Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Acquired Orphan Blood Diseases Therapeutics Revenue by Countries

6.1 Europe Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue by Countries

7.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

7.2 China Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Acquired Orphan Blood Diseases Therapeutics Revenue by Countries

8.1 South America Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Acquired Orphan Blood Diseases Therapeutics by Countries

9.1 Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Acquired Orphan Blood Diseases Therapeutics Market Segment by Type

10.1 Global Acquired Orphan Blood Diseases Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Acquired Orphan Blood Diseases Therapeutics Market Forecast by Type (2018-2023)

10.3 Medication Revenue Growth Rate (2013-2023)

10.4 Bone Marrow Transplant Revenue Growth Rate (2013-2023)

10.5 Blood Transfusion Revenue Growth Rate (2013-2023)

10.6 Iron Therapy Revenue Growth Rate (2013-2023)

11 Global Acquired Orphan Blood Diseases Therapeutics Market Segment by Application

11.1 Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Acquired Orphan Blood Diseases Therapeutics Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

11.5 Others Revenue Growth (2013-2018)

12 Global Acquired Orphan Blood Diseases Therapeutics Market Size Forecast (2018-2023)

12.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size Forecast (2018-2023)

12.2 Global Acquired Orphan Blood Diseases Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures



Figure Acquired Orphan Blood Diseases Therapeutics Picture

Table Product Specifications of Acquired Orphan Blood Diseases Therapeutics

Table Global Acquired Orphan Blood Diseases Therapeutics and Revenue (Million USD) Market Split by Product Type

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Types in 2017

Figure Medication Picture

Figure Bone Marrow Transplant Picture

Figure Blood Transfusion Picture

Figure Iron Therapy Picture

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Application (2013-2023)

Figure Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Applications in 2017

Figure Hospitals Picture

Figure Clinics Picture

Figure Others Picture

Table Global Market Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) Comparison by Regions 2013-2023

Figure North America Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Europe Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure South America Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (2013-2023)

Table Alexion Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Amgen Basic Information, Manufacturing Base and Competitors

Table Amgen Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Amgen Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Celgene Corporation Basic Information, Manufacturing Base and Competitors

Table Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Eli Lilly Basic Information, Manufacturing Base and Competitors

Table Eli Lilly Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Eli Lilly Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Sanofi Basic Information, Manufacturing Base and Competitors

Table Sanofi Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Sanofi Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors

Table GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Cyclacel Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Onconova Therapeutics Basic Information, Manufacturing Base and Competitors

Table Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Incyte Corporation Basic Information, Manufacturing Base and Competitors

Table Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table CTI BioPharma Basic Information, Manufacturing Base and Competitors

Table CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Type and Applications

Table CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Players (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Players (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Players in 2016

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Players in 2017

Figure Global Top 5 Players Acquired Orphan Blood Diseases Therapeutics Revenue Market Share in 2017

Figure Global Top 10 Players Acquired Orphan Blood Diseases Therapeutics Revenue Market Share in 2017

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate (%) (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Regions (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Regions (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Regions (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Regions in 2017

Figure North America Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Europe Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure South America Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Table North America Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

Table North America Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure North America Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure North America Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries in 2017

Figure USA Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Canada Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Mexico Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Table Europe Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Countries (2013-2018)

Figure Europe Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Europe Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries in 2017

Figure Germany Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure UK Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure France Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Russia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Italy Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Table Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Countries (2013-2018)

Figure Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries in 2017

Figure China Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Japan Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Korea Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure India Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Southeast Asia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Table South America Acquired Orphan Blood Diseases Therapeutics Revenue by Countries (2013-2018)

Table South America Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure South America Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure South America Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries in 2017

Figure Brazil Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Argentina Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Colombia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Table Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Countries (2013-2018)

Table Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Countries in 2017

Figure Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure UAE Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Egypt Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure Nigeria Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Figure South Africa Acquired Orphan Blood Diseases Therapeutics Revenue and Growth Rate (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) by Type (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Type (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Type (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Type in 2017

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue Forecast by Type (2018-2023)

Figure Global Acquired Orphan Blood Diseases Therapeutics Market Share Forecast by Type (2018-2023)

Figure Global Medication Revenue Growth Rate (2013-2018)

Figure Global Bone Marrow Transplant Revenue Growth Rate (2013-2018)

Figure Global Blood Transfusion Revenue Growth Rate (2013-2018)

Figure Global Iron Therapy Revenue Growth Rate (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue by Application (2013-2018)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Application (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Application (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Share by Application in 2017

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue Forecast by Application (2018-2023)

Figure Global Acquired Orphan Blood Diseases Therapeutics Market Share Forecast by Application (2018-2023)

Figure Global Hospitals Revenue Growth Rate (2013-2018)

Figure Global Clinics Revenue Growth Rate (2013-2018)

Figure Global Others Revenue Growth Rate (2013-2018)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) and Growth Rate Forecast (2018 -2023)

Table Global Acquired Orphan Blood Diseases Therapeutics Revenue (Million USD) Forecast by Regions (2018-2023)

Figure Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share Forecast by Regions (2018-2023)

Figure North America Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

Figure Europe Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

Figure Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

Figure South America Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)

Figure Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Market Forecast (2018-2023)



【掲載企業】

Alexion Pharmaceuticals、Amgen、Celgene Corporation、Eli Lilly、Sanofi、GlaxoSmithKline、Cyclacel Pharmaceuticals、Onconova Therapeutics、Incyte Corporation、CTI BioPharma

【レポートのキーワード】

後天性希少血液疾患治療薬、薬、骨髄移植、輸血、鉄療法、病院、診療所、その他

★調査レポート[後天性希少血液疾患治療薬の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)] (コード:GIR8100012)販売に関する免責事項を必ずご確認ください。
★調査レポート[後天性希少血液疾患治療薬の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆